Prevail Therapeutics to Present at The Jefferies Virtual Global Healthcare Conference
Prevail Therapeutics (Nasdaq: PRVL) is set to present at the Jefferies Virtual Global Healthcare Conference on June 2, 2020, at 3:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prevail Therapeutics (Nasdaq: PRVL) is set to present at the Jefferies Virtual Global Healthcare Conference on June 2, 2020, at 3:30 p.m. ET. CEO Asa Abeliovich will provide insights into the company's gene therapies aimed at neurodegenerative diseases. The presentation will be accessible via a live webcast and archived for 90 days on their website. Prevail focuses on AAV-based treatments like PR001 for Parkinson's disease with GBA1 mutations, PR006 for frontotemporal dementia, and PR004 for certain synucleinopathies.
Details
News Market Reaction – PRVL
The recorded move for PRVL in the trading session of this news was -2.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m. ET.
A live webcast of the presentation will be available under “Events and Presentations” in the Investors & Media section of the company's website, www.prevailtherapeutics.com. The webcast will be archived for 90 days following the event.
About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.
Media Contact:
Mary Carmichael
Ten Bridge Communications
mary@tenbridgecommunications.com
617-413-3543
Investor Contact:
investors@prevailtherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.